Personal Genome Diagnostics Appoints Megan Bailey as Chief Executive Officer
BALTIMORE, MD, (April 21, 2020) – Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, appointed Megan Bailey as Chief Executive Officer (CEO), promoted from Chief Commercial Officer (CCO). Bailey succeeds Douglas Ward, who has served as PGDx’s Chief Executive Officer since 2016.
“PGDx is at the forefront of cancer genomics with a vision to fundamentally change oncology care by delivering products that enable local precision medicine,” said Luis Diaz, MD, Co-Founder and Chairman, Personal Genome Diagnostics. “Megan has made significant contributions since joining the company, and her leadership will be critical as we prepare for the next phase of commercial success. Megan’s extensive knowledge of clinical diagnostics, along with business development and commercialization expertise is perfectly aligned with the next stages of growth for the company.”
Prior to her appointment to Chief Executive Officer, Bailey joined PGDx as the Vice President of Marketing and was promoted to Chief Commercial Officer, where she led the company’s marketing, sales, customer support, and communications in developing and executing global go-to-market strategies. During her tenure at PGDx, Bailey contributed to CE marks for both the elio™ tissue complete assay and elio™ plasma resolve products and played a key role in establishing strategic collaborations with organizations such as the Mayo Clinic and PathGroup.
Before joining PGDx, Bailey spent more than 14 years at Roche. Most recently, Bailey served as Senior Director of Commercial Operations, responsible for leading sales teams across Roche’s Clinical Chemistry/Immunoassay, Molecular, Tissue, and Point of Care divisions in the Southeast United States. Prior to that she held marketing leadership roles for the Tissue Diagnostics division where she led multiple product launches, developed and executed commercial strategies across a variety of product lines, and drove strategic collaborations with some of the nation’s largest Integrated Health Networks.
“I am honored to have the opportunity to lead PGDx at this point in the company’s evolution,” said Megan Bailey, Chief Executive Officer, Personal Genome Diagnostics. “We’re on the cusp of enabling the scalability of precision medicine with a fast, reliable, and accurate system through the upcoming launch of PGDx elio™ tissue complete. I’m thrilled to continue to work with our world-class team to deliver diagnostic products to healthcare systems that empower the fight against cancer for patients and clinicians.”
Dr. Diaz added: “On behalf of the PGDx Board of Directors, I would like to extend our sincere gratitude to Doug Ward for his vision, expertise and commitment to PGDx that enabled us to be a commercially oriented organization poised to deliver best-in-class products to healthcare systems worldwide.”
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic
products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. For additional
information, visit www.PersonalGenome.com.
Latest posts by Chris Frew (see all)
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
- Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
- SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021